中晚期食管癌同期放化疗DO方案与PF方案配对近期疗效分析

目的比较多西紫杉醇＋奥沙利铂（DO方案）与顺铂＋5-氟尿嘧啶（PF方案）在中晚期食管癌同期放化疗中疗效差别。方法选择72例中晚期食管癌患者。配对分为DO方案同期放化疗组和PF方案同期放化疗组，分别于放疗结束时和放疗后3个月观察两组近期疗效。结果①DO组和PF组放疗结束时有效率分别为94．44％和88．89％（P=0．394），两组放疗后3个月的有效率分别为97．22％和72．22％（P=0．003）。DO组和PF组放疗结束时局部病灶完全缓解率分别为22．22％和25．00％（P=0．781），两组放疗后3个月局部病灶完全缓解率分别为75．00％和50．00％（P=0．028）。②DO组外周神经炎、贫血发生率较高，而消化道反应、白细胞减少较PF组发生率低。结论DO方案同期放化疗与PF方案同期放化疗相比，放疗后3个月有效率和完全缓解率显著提高，毒性可耐受，值得进一步研究。

Short-term Effect Analysis of Docetaxol and Oxaliplatinvs Cisplatin and 5-FU in Concurrent Chemoradiotherapy for Advanced Esophageal Cancer

Objective Compared the short-term effect rates and toxicities of Docetaxol Oxaliplatin （DO） with DDP 5-FU（PF）used in concomitant chemoradiotherapy of advanced esophageal cancer.Methods 72 patients with advanced esophageal cancer were divided into DO group （treatment group）radiation with concurrent chemotherapy Docetaxol Oxaliplatin and PF group（compare group） radiation with concurrent chemotherapy DDP 5-FU.Each patient in the DO group was matched with another patient from PF group.The responses in the end of the radiotherapy and 3 months were evaluated after radiotherapy.Results （1） In the end of radiotherapy, the overall responses in DO group and in PF group were 94.44 % and 88.89 %.The complete remissons of DO group and in PF group were 22.22 % and 25.00 %.3 months after the end of radiotherapy,the overall responses of the DO group and the PF group were 97.22 % and 72.22 %; the complete remissions of two groups were respectively 75.00 % and 50.00 %; 3 months after the end of radiotherapy, comparing CR rates of the two groups, there were significant differences （P 〈0.05）;（2） Incidences of hematological and peripheral nerves toxicities in DO group were higher than those in PF group. Gastrointestinal reactions and leucopenia were less frequent in DO group than in PF group.Conclusions 3 months after radiotherapy, radiation with concurrent chemotherapy Docetaxol Oxaliplatin significantly improves the overall responses and the complete remissions.Toxicities can be tolerated. Radiotherapy with concurrent chemotherapy Docetaxol is waranted to further study.